image
Healthcare - Medical - Devices - NASDAQ - IL
$ 15.4
-1.97 %
$ 1.07 B
Market Cap
6.84
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one INMD stock under the worst case scenario is HIDDEN Compared to the current market price of 15.4 USD, InMode Ltd. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one INMD stock under the base case scenario is HIDDEN Compared to the current market price of 15.4 USD, InMode Ltd. is HIDDEN

This DCF valuation model was last updated on Apr, 8, 2025.

The intrinsic value of one INMD stock under the best case scenario is HIDDEN Compared to the current market price of 15.4 USD, InMode Ltd. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INMD

image
$20.0$20.0$19.5$19.5$19.0$19.0$18.5$18.5$18.0$18.0$17.5$17.5$17.0$17.0$16.5$16.5$16.0$16.0$15.5$15.5$15.0$15.015 Oct15 OctNov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '25
FINANCIALS
395 M REVENUE
-19.76%
113 M OPERATING INCOME
-42.49%
181 M NET INCOME
-8.41%
133 M OPERATING CASH FLOW
-24.97%
162 M INVESTING CASH FLOW
219.21%
-283 M FINANCING CASH FLOW
-5137.55%
97.9 M REVENUE
-24.86%
27.9 M OPERATING INCOME
-42.26%
82.8 M NET INCOME
62.33%
32.4 M OPERATING CASH FLOW
-4.72%
77.8 M INVESTING CASH FLOW
-31.77%
-118 M FINANCING CASH FLOW
-55.85%
Balance Sheet InMode Ltd.
image
Current Assets 714 M
Cash & Short-Term Investments 596 M
Receivables 41.1 M
Other Current Assets 76.9 M
Non-Current Assets 71.2 M
Long-Term Investments 700 K
PP&E 11.1 M
Other Non-Current Assets 59.5 M
75.92 %5.22 %9.79 %7.57 %Total Assets$785.7m
Current Liabilities 69.9 M
Accounts Payable 13.8 M
Short-Term Debt 2.51 M
Other Current Liabilities 53.6 M
Non-Current Liabilities 12 M
Long-Term Debt 5.31 M
Other Non-Current Liabilities 6.69 M
16.84 %3.07 %65.43 %6.49 %8.18 %Total Liabilities$81.9m
EFFICIENCY
Earnings Waterfall InMode Ltd.
image
Revenue 395 M
Cost Of Revenue 77.8 M
Gross Profit 317 M
Operating Expenses 205 M
Operating Income 113 M
Other Expenses -68.7 M
Net Income 181 M
400m400m350m350m300m300m250m250m200m200m150m150m100m100m50m50m00395m(78m)317m(205m)113m69m181mRevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
80.31% GROSS MARGIN
80.31%
28.50% OPERATING MARGIN
28.50%
45.91% NET MARGIN
45.91%
25.76% ROE
25.76%
23.07% ROA
23.07%
19.79% ROIC
19.79%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis InMode Ltd.
image
200m200m180m180m160m160m140m140m120m120m100m100m80m80m60m60m40m40m20m20m00201720172018201820192019202020202021202120222022202320232024202420252025
Net Income 181 M
Depreciation & Amortization 728 K
Capital Expenditures -669 K
Stock-Based Compensation 16.6 M
Change in Working Capital -7.07 M
Others 3.66 M
Free Cash Flow 132 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets InMode Ltd.
image
Wall Street analysts predict an average 1-year price target for INMD of $21.4 , with forecasts ranging from a low of $16 to a high of $27 .
INMD Lowest Price Target Wall Street Target
16 USD 3.90%
INMD Average Price Target Wall Street Target
21.4 USD 38.96%
INMD Highest Price Target Wall Street Target
27 USD 75.32%
Price
Max Price Target
Min Price Target
Average Price Target
28282626242422222020181816161414May '24May '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 12
6. Ownership
Insider Ownership InMode Ltd.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade) I upgrade InMode to Buy due to improved capital allocation, including significant share buybacks and potential for record dividends. Despite a 20% revenue decline in 2024, InMode remains a strong cash generator, with $600 million in cash. Conservative DCF valuation suggests a fair value of $21.67 per share, implying a 22.5% potential upside from current levels. seekingalpha.com - 1 week ago
3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally Three discounted MedTech stocks to gain from the market rebound are PAHC, FMS and INMD. zacks.com - 2 weeks ago
InMode to Present at the 24th Annual Needham Virtual Healthcare Conference YOKNEAM, Israel , March 26, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer, and Yair Malca, Chief Financial Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025. prnewswire.com - 2 weeks ago
Is InMode (INMD) Stock Undervalued Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. zacks.com - 2 weeks ago
InMode Responds to Doma Perpetual's Letters Clarifies Capital Allocation Strategy and Commitment to Shareholder Returns Refutes Misconceptions on Staffing and Production Asserts No Justification for Additional Legal Action YOKNEAM, Israel , March 6, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated January 15, 2025. prnewswire.com - 1 month ago
InMode to Present at Upcoming Investor Conferences YOKNEAM, Israel , March 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March: Barclays 27th Annual Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer  Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetings Location: Miami, FL When: Wednesday, March 12 at 9:00 am EDT A live webcast of the presentation can be accessed here. prnewswire.com - 1 month ago
InMode: Plastic Surgery Boom, Cash Flow, And Cheap InMode is significantly undervalued, with strong cash flow, international expansion, and investments in research and marketing driving future revenue and free cash flow growth. The company benefits from the booming non-invasive plastic surgery market, expected to grow at a 14% CAGR from 2023 to 2030. INMD's stock repurchase program and substantial investments in bonds and bank deposits are expected to boost stock price and financial stability. seekingalpha.com - 2 months ago
InMode Ltd. (INMD) Q4 2024 Earnings Call Transcript InMode Ltd. (NASDAQ:INMD ) Q4 2024 Results Conference Call February 4, 2025 8:30 AM ET Company Participants Miri Segal - CEO, MS-IR Moshe Mizrahy - Chief Executive Officer Michael Kreindel - Chief Technology Officer Yair Malca - Chief Financial Officer Rafael Lickerman - Vice President, Finance Conference Call Participants Danielle Antalffy - UBS Matt Miksic - Barclays Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Mike Matson - Needham & Company Jeff Johnson - Baird Sam Eiber - BTIG Operator Good day, and welcome to the InMode Fourth Quarter and Full Year 2024 Earnings Results Conference Call. seekingalpha.com - 2 months ago
InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program Quarterly GAAP revenues of $ 97.9   million and full year revenue of $394.8 million Returned $285.4 million of capital to shareholders in full year 2024  Together with new 10% program, represents repurchase of approximately 27% of shares outstanding within 15 month timeframe, with the potential of substantial additional capital return in 2025 YOKNEAM, Israel, Feb. 4, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year 2024. prnewswire.com - 2 months ago
InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference YOKNEAM, Israel , Feb. 3, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference in Snowbird, UT on Wednesday, February 12, 2025. prnewswire.com - 2 months ago
InMode: A Clear Bargain With Unique Risks InMode Ltd. boasts superior fundamentals, yet trades at undervalued market multiples due to its unique risk profile. The company is a leader in the global aesthetics market with proprietary RF-based technologies. InMode's robust balance sheet and high profit margins support a substantial margin of safety at current prices, despite risks. seekingalpha.com - 2 months ago
InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced Conference call rescheduled to Tuesday, February 4, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 16, 2025 /PRNewswire/ -- InMode Ltd. prnewswire.com - 2 months ago
8. Profile Summary

InMode Ltd. INMD

image
COUNTRY IL
INDUSTRY Medical - Devices
MARKET CAP $ 1.07 B
Dividend Yield 0.00%
Description InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.
Contact Tavor Building, Yokne'am, 2069206 https://www.inmodemd.com
IPO Date Aug. 8, 2019
Employees 599
Officers Ms. Nava Tal-Launer Chief Information Officer Mr. Michael Dennison Vice President of Sales - East US Mr. Matt Rodgers Vice President of Sales of Canada Mr. Brandon Nye Vice President of Sales of West US Mr. Moshe Mizrahy Co-Founder, Chief Executive Officer & Director Mr. Yair Malca Chief Financial Officer Dr. Michael Kreindel Co-Founder, Chief Technology Officer & Director